RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Mantle Cell Lymphoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Common presentation of an uncommon entity: nasopharyngeal mantle cell lymphoma
Swati Mishra et al., IP Journal of Otorhinolaryngology and Allied Science (16 October 2026)
https://doi.org/10.18231/j.ijoas.18661.1791178180
- 2.
Spurious CD34 expression in mantle cell lymphoma due to non-specific binding to PerCP-Cy5.5: A diagnostic pitfall.
Krishnan Abhilash et al., Cytometry. Part B, Clinical cytometry (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42876323/
- 3.
Molecular biomarkers as key determinants of outcome in mantle cell lymphoma: results from the FIL V-RBAC trial.
Moia Riccardo et al., Blood advances (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42498280/
- 4.
Improving survival and narrowing age disparities in mantle cell lymphoma across therapeutic eras.
Munir Malak et al., Blood cancer journal (13 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42869895/
- 5.
Safety and effectiveness of ibrutinib in indian patients with chronic lymphocytic leukemia and mantle cell lymphoma: Results from a prospective phase 4 post-marketing study
Pankaj Malhotra et al., Onco Critical Care. (5 October 2026)
https://doi.org/10.18231/j.occ.18599.1791191943
Clinical Trials : Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
NCT06742996 · Recruiting · Phase 3 · BeOne Medicines
Ages 18 and over
https://clinicaltrials.gov/study/NCT06742996
- 2.
A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
NCT06697184 · Recruiting · Phase 1 / Phase 2 · BeOne Medicines
Ages 18 and over
https://clinicaltrials.gov/study/NCT06697184
- 3.
A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma
NCT06084936 · Recruiting · Phase 3 · Hoffmann-La Roche
Ages 18 and over
https://clinicaltrials.gov/study/NCT06084936
- 4.
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT06022029 · Recruiting · Phase 1 · OncoNano Medicine, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT06022029
- 5.
A Phase 2 Trial of GlOfitamab anD pIrtobrutinib in Mantle Cell Lymphoma Patients With Prior BTK Inhibitor Exposure.
NCT05833763 · Recruiting · Phase 2 · Australasian Leukaemia and Lymphoma Group
Ages 18 and over
https://clinicaltrials.gov/study/NCT05833763
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Mantle Cell Lymphoma
Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma that starts in B cells in the mantle zone of the lymph nodes. It can affect the lymph nodes, spleen, bone marrow and gut. Some people need treatment straight away, while others are monitored first. Treatment may include chemotherapy, immunotherapy, targeted medicines and stem cell transplant.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Mantle cell lymphoma (MCL) is an uncommon and belligerent subtype of mature B-cell non-Hodgkin lymphoma, making up 5–10% of all lymphomas. Primary involvement of the nasopharynx is exceptionally uncommon and often presents with nonspecific symptoms, leading to delayed diagnosis. We report the case of a 45-year-old female who presented with dysphagia, bilateral neck swellings, and change in voice. Imaging revealed a nasopharyngeal mass with cervical lymphadenopathy. Histopathological examination demonstrated a monomorphic proliferation of small- to medium-sized lymphoid cells with irregular nuclear contours. Immunohistochemistry (IHC) revealed positivity for CD20, CD5, and cyclin D1, with a Ki-67 proliferative index of 70%, confirming mantle cell lymphoma. Despite initiation of systemic chemotherapy, the patient developed rapid disease progression and died within one month of diagnosis. This case highlights aggressiveness of nasopharyngeal MCL and underscores the importance of early histopathological diagnosis and immunohistochemical evaluation for timely recognition and appropriate management of this rare extra-nodal malignancy.Key words: Biopsy, Lymph nodes, Nasopharynx, Non-hodgkin lymphoma, Stem cell transplantation, Waldeyer ring
Common Questions
What is Mantle Cell Lymphoma?
Mantle cell lymphoma is a rare type of non-Hodgkin lymphoma that starts in B cells in the mantle zone of the lymph nodes. It can affect the lymph nodes, spleen, bone marrow and gut. Some people need treatment straight away, while others are monitored first. Treatment may include chemotherapy, immunotherapy, targeted medicines and stem cell transplant.
How many clinical trials are available for Mantle Cell Lymphoma?
RareWays currently indexes 664 clinical trials for Mantle Cell Lymphoma, of which 85 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Mantle Cell Lymphoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Mantle Cell Lymphoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.